Allurion Technologies Inc.
- Industry
- Medical Devices
- Founded Year
- 2009
- Headquarters
- 11 Huron Drive, Natick, MA 01760, United States
- Employee Count
- 267
Key People
- Dr. Shantanu K. Gaur M.D. - Co-Founder, CEO, President & Director
- Mr. Christopher Geberth - CFO & Treasurer
- Dr. Samuel G. Levy - Co-Founder
- Dr. Ram Chuttani M.D. - Chief Medical Officer & Founding Partner
- Mr. Ojas A. Buch - Chief Operating Officer
- Mr. Brendan Michael Gibbons - Chief Legal Officer & Corporate Secretary
- Mr. Matt Wright - Vice President of People
- Ms. Joyce Johnson - Senior Vice President of Regulatory Affairs & Quality Assurance
Assessment
- Team
-
Aspect: Multiple successful MedTech entrepreneurs
Summary: The leadership team comprises experienced professionals with backgrounds in medical technology and business operations.
The leadership includes individuals with significant experience in the medical device industry, enhancing the company's capability to navigate market challenges and drive product development.
- Clinical Need
-
Aspect: Very Strong
Summary: Obesity is a global health crisis with limited effective non-surgical interventions.
With over 2 billion people worldwide classified as overweight, the demand for effective, non-invasive weight loss solutions is substantial, providing a strong market opportunity for Allurion's products.
- Competition
-
Aspect: Very crowded + Strategics
Summary: The weight loss market is highly competitive, with numerous pharmaceutical and medical device companies.
The presence of established players like Novo Nordisk and Eli Lilly, offering GLP-1 drugs, poses significant competition to Allurion's gastric balloon technology.
- Technical Challenge
-
Aspect: Predictable
Summary: The technology involves a swallowable, self-inflating gastric balloon with a controlled release mechanism.
While the concept is novel, the underlying technology leverages existing knowledge in medical device engineering, reducing development risks.
- Patent
-
Aspect: Strong
Summary: The company holds a robust patent portfolio covering its gastric balloon technology.
As of December 31, 2024, Allurion owns or has rights to 19 issued patents and six pending applications in the U.S., along with 42 issued and five pending patents internationally, providing substantial protection for its innovations.
- Financing
-
Aspect: Well-funded
Summary: The company has secured significant funding from reputable investors.
Allurion has raised substantial capital, including a $48 million convertible senior secured note financing with RTW Investments in April 2024, enhancing its financial stability.
- Regulatory
-
Aspect: Pivotal Trial
Summary: The company is progressing through regulatory pathways, including FDA submissions.
Allurion has submitted multiple modules of its premarket approval application to the FDA and anticipates submitting the final module containing clinical data from the AUDACITY trial, aiming for U.S. market entry.
Opportunity Rollup
- Odds of Success
- 3.45
- Peak Market Share
- 4
- Segment CAGR
- 6.3%
- Market Segment
- Medical Devices
- Market Sub Segment
- Weight Loss Devices
| Year Post Launch | Market Penetration (%) |
|---|---|
| 1 | 0.20 |
| 2 | 0.60 |
| 3 | 1.40 |
| 4 | 2.80 |
| 5 | 4.00 |
Key Takeaway
Allurion Technologies offers an innovative, non-invasive weight loss solution with strong clinical need and a robust patent portfolio, but faces significant competition and regulatory challenges in a crowded market.